<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134304">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01661179</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00098</org_study_id>
    <nct_id>NCT01661179</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma</brief_title>
  <official_title>A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in
      Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid
      Carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300
      mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary
      Thyroid Carcinoma
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>During the treatment period and than up to 60 days after treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc Bazett's absolute values</measure>
    <time_frame>During the treatment period and than up to 60 days after treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs including pulse rate, blood pressure and temperature</measure>
    <time_frame>During the treatment period and than up to 60 days after treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematology and clinical chemistry absolute values</measure>
    <time_frame>During the treatment period and than up to 60 days after treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Pre-dose and 85, 169, 253, 337 and 421 days post first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of vandetanib</measure>
    <time_frame>8,15,22,29,57,85,113,141,169,197,225,253 days post first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters for multiple dose: Maximum Concentration (Cmax),Time to Maximum Plasma Concentration (tmax), and Area Under Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between pharmacokinetics and pharmacodynamics.</measure>
    <time_frame>8,15,22,29,57,85,113,141,169,197,225,253 days post first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relationship between vandetanib plasma concentration and effect on QTc. If appropriate, concentration-effect relationships will be explored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Pre-dose and 85, 169, 253, 337 and 421 days post first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vandetanib 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg/day vandetanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib 300mg</intervention_name>
    <description>300 mg oral dose once daily (100 mg x 3 tablets)</description>
    <arm_group_label>Vandetanib 300mg</arm_group_label>
    <other_name>ZD6474</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent from female or male Japanese patients aged 20 years and over.
             Evidence of non-childbearing status for women of childbearing potential, or
             postmenopausal status.

          -  Previous diagnosis of unresectable, locally advanced or metastatic, hereditary or
             sporadic Medullary Thyroid Carcinoma(MTC).

          -  Patients who have a good overall health status(World Health Organization (WHO)
             Performance status 0-2).

          -  Patients who have appropriate renal conditions confirmed by test results for taking
             part in the study.

          -  For patients with measurable disease(at least one lesion, not irradiated within 12
             weeks of study registration, with longest diameter more or equal 10mm (lymph nodes
             minimum more or equal 15 mm) with CT or MRI).

        Exclusion Criteria:

          -  Patients with brain metastases or spinal cord compression.

          -  Patients with significant abnormal ECG (QTcB correction unmeasurable or more than 480
             ms)findings and /or significant cardiac conditions or events, uncontrolled
             hypertension and evidence of severe lung disease.

          -  Abnormal electrolytes such as potassium, magnesium and calcium, or abnormal organ
             functions such as decreased creatinine clearance.

          -  Patients with significant abnormal laboratory findings (to include abnormal liver
             function tests (bilirubin more than 1.5xULRR, and ALT, AST, or ALP more than 2.5xULRR
             or 5.0xULRR if related to liver metastases).

          -  Prior treatment (major surgery, radiation therapy, chemotherapy, or other
             investigational drugs) received within 28 days before registration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Skolnik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takahiro Okamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Women's Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keita Uchino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organization Kyushu Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>July 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medullary Thyroid Carcinoma</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>Vandetanib</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
